Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Development of synthetic lethality anticancer therapeutics.

Fang B.

J Med Chem. 2014 Oct 9;57(19):7859-73. doi: 10.1021/jm500415t. Epub 2014 Jun 13. Review.

2.

Targeting the DNA damage response in oncology: past, present and future perspectives.

Basu B, Yap TA, Molife LR, de Bono JS.

Curr Opin Oncol. 2012 May;24(3):316-24. doi: 10.1097/CCO.0b013e32835280c6. Review.

PMID:
22476188
3.

Synthetic lethality-based targets for discovery of new cancer therapeutics.

Weidle UH, Maisel D, Eick D.

Cancer Genomics Proteomics. 2011 Jul-Aug;8(4):159-71. Review.

PMID:
21737609
4.

Synthetic lethality-based therapeutics: perspectives for applications in colorectal cancer.

Soncini D, Caffa I, Patrone F, Ballestrero A, Nencioni A.

Curr Cancer Drug Targets. 2012 May;12(4):329-38. Review.

PMID:
22385509
5.

Embracing synthetic lethality of novel anticancer therapies.

Kamal A, Shaik TB, Malik MS.

Expert Opin Drug Discov. 2015 Oct;10(10):1119-32. doi: 10.1517/17460441.2015.1072167. Epub 2015 Jul 27. Review.

PMID:
26211783
6.

[From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].

Schreiber V, Illuzzi G, Héberlé E, Dantzer F.

Bull Cancer. 2015 Oct;102(10):863-73. doi: 10.1016/j.bulcan.2015.07.012. Epub 2015 Sep 15. Review. French.

PMID:
26384693
7.

Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors.

Lord CJ, Tutt AN, Ashworth A.

Annu Rev Med. 2015;66:455-70. doi: 10.1146/annurev-med-050913-022545. Epub 2014 Oct 17. Review.

PMID:
25341009
8.

Applying synthetic lethality for the selective targeting of cancer.

McLornan DP, List A, Mufti GJ.

N Engl J Med. 2014 Oct 30;371(18):1725-35. doi: 10.1056/NEJMra1407390. Review. No abstract available.

PMID:
25354106
9.

Mechanisms of resistance to therapies targeting BRCA-mutant cancers.

Lord CJ, Ashworth A.

Nat Med. 2013 Nov;19(11):1381-8. doi: 10.1038/nm.3369. Epub 2013 Oct 7. Review.

PMID:
24202391
10.

Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.

Ogiwara H, Ui A, Shiotani B, Zou L, Yasui A, Kohno T.

Carcinogenesis. 2013 Nov;34(11):2486-97. doi: 10.1093/carcin/bgt240. Epub 2013 Jul 3.

PMID:
23825154
11.

Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective.

Sandhu SK, Yap TA, de Bono JS.

Eur J Cancer. 2010 Jan;46(1):9-20. doi: 10.1016/j.ejca.2009.10.021. Review.

PMID:
19926276
12.
13.

Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.

Dedes KJ, Wilkerson PM, Wetterskog D, Weigelt B, Ashworth A, Reis-Filho JS.

Cell Cycle. 2011 Apr 15;10(8):1192-9. Epub 2011 Apr 15.

14.

DNA repair and synthetic lethality.

Guo GS, Zhang FM, Gao RJ, Delsite R, Feng ZH, Powell SN.

Int J Oral Sci. 2011 Oct;3(4):176-9. doi: 10.4248/IJOS11064. Review.

15.

Differences in Expression of Key DNA Damage Repair Genes after Epigenetic-Induced BRCAness Dictate Synthetic Lethality with PARP1 Inhibition.

Wiegmans AP, Yap PY, Ward A, Lim YC, Khanna KK.

Mol Cancer Ther. 2015 Oct;14(10):2321-31. doi: 10.1158/1535-7163.MCT-15-0374. Epub 2015 Aug 20.

16.
17.

Response of subtype-specific human breast cancer-derived cells to poly(ADP-ribose) polymerase and checkpoint kinase 1 inhibition.

Shibata H, Miuma S, Saldivar JC, Huebner K.

Cancer Sci. 2011 Oct;102(10):1882-8. doi: 10.1111/j.1349-7006.2011.02016.x. Epub 2011 Jul 21.

18.

Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.

Oplustilova L, Wolanin K, Mistrik M, Korinkova G, Simkova D, Bouchal J, Lenobel R, Bartkova J, Lau A, O'Connor MJ, Lukas J, Bartek J.

Cell Cycle. 2012 Oct 15;11(20):3837-50. doi: 10.4161/cc.22026. Epub 2012 Sep 14.

19.

Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic.

Yap TA, Sandhu SK, Carden CP, de Bono JS.

CA Cancer J Clin. 2011 Jan-Feb;61(1):31-49. doi: 10.3322/caac.20095. Epub 2011 Jan 4. Review.

20.

New opportunities in chemosensitization and radiosensitization: modulating the DNA-damage response.

Luo Y, Leverson JD.

Expert Rev Anticancer Ther. 2005 Apr;5(2):333-42. Review.

PMID:
15877529

Supplemental Content

Support Center